Researchers at the University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three summaries of minigorgia at the annual meeting of the American Cancer Union (AACR). State in pancreatic cancer.
In addition to these tests, upcoming press releases will include remarkable summaries of oral and plenary. More information on all annual MD Anderson AACR meeting can be found at Mdanderson.org/Aacr.
Personalized vaccine with or without immunotherapy is safe for patients with metastatic colon cancer subtype (CT012 summary)
Patients with metastatic colon cancer who are stable with microstrodoges (MSS MCRC) have poor areas and limited treatment options after failure of typical chemotherapy, partly due to immunologically “cold” micro -pervasive tumor. Researchers, led by Saurav Daniel Haldar, MD and Michael Overman, MD, developed a personalized vaccine platform called Neoag-Vax using bioinformatics and sequence tools for the production of up to 10 proteins derived from volume targeting each. In this Phase I feasibility study, researchers combine the personalized vaccine with and without pembrolizumab immunotherapy in 28 patients with MSS MCRC. The personalized vaccine was safe and feasible for administration, leading to strong immune reactions to most patients who were vaccinated in this study. The researchers also described the synthesis of immunocytes within the tumors of patients, providing molecular knowledge to the immune microenval that could inform future therapeutic approaches. Haldar will present the results on April 27.
Radiotherapy -directed metastasis avoids toxicities of systemic treatment in patients with clear renal cell carcinoma (abstract CT132)
Systematic treatments used for patients with metastatic renal cell carcinoma (CCRCC), such as immunotherapy and tyrosine kinase inhibitors, are associated with high rates of toxicity. Radiotherapy directed by metastasis can limit the side effects, but there are no established biomarkers to detect patients who are more likely to respond. As a result, researchers led by Chad Tang, MD and Pavlos Msaouel, MD, Ph.D., conducted a phase II perspective test investigating metastasis treatment without systemic treatment in 121 patients with oligomatic CCRCC. The average survival (PFS) was 18 months, with median survival without a 34 -month systematic treatment (STFS). It is important that overall survival (OS) is not at stake, with 94% OS rates and 87% in two and three years, respectively. The researchers also examined a new test that updates the tumor tumor (CTDNA) of the detection of molecular residual disease (MRD). Patients who were MRD versus MRD+ at start had an average 54 -month STF compared to 27 months. These findings show that metastasis -directed radiotherapy can help patients avoid systemic therapies without ending the results and that the CTDNA test is a useful personalized prognostic biomarker for response. Tang will present the results on April 28.
Extravagant provides gene cigratory For Kras G12D Pancreatic Cancer (CT265 Summary)
Kras g12d Mutations occur in more than 40% of pancreatic cancer cases, but KRAS inhibitors have not attributed resistant responses to patients, partly due to an immunosuppressive microenval tumor. Extravagant are small extracellular vesicles that can be made to carry a small interference RNA (sirna), which is silent on specific genes into cancer cells. In a first -dose -dose -to -human dose test, researchers led by Valerie Lebleu, MD, Ph.D., Shubham Pant, MD, Elizabeth Shpall, MD and Brandon Smaglo, MD Kras g12d In 12 patients with metastatic pancreatic cancer. Six of the 12 patients who received all doses of extracurricular had a stable disease in target lesions and there were no dose limitation toxicities. Researchers noted a decrease Kras g12d circulating DNA after treatment. Further in vivo The analysis revealed that these extracurricular would work well with the exclusion of the immune control point to reschedule the microenval of the tumor and to overcome the treatment resistance, emphasizing the combination as a possible therapeutic strategy investigated in an upcoming phase II.
In addition, the Abstract CT267 features early clinical trial data from the ATR, ATR, ART0380 inhibitor, in advanced compact tumors. This targeted treatment was first discovered and developed by MD Anderson’s Discovery Discovery and has been licensed at Artios Pharma. Preclinical and translation studies led by researchers at MD Anderson, published in Clinical research on cancerIt demonstrated a strong anti -cancer activity and established an innovative approach to optimize the choice of patients based on molecular tumor characteristics.
